-
Establishing a Differential Marker Profile for Pregnancy Complications Near Delivery.
Sharabi-Nov A, Kumar K, Fabjan Vodušek V, Premru Sršen T, Tul N, Fabjan T, Meiri H, Nicolaides KH, Osredkar J.
Fetal Diagn Ther 2020;47:471-484. pdf -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Prediction of spontaneous preterm delivery from maternal factors, obstetric history and placental perfusion and function at 11-13 weeks.
Beta J, Akolekar R, Ventura W, Syngelaki A, Nicolaides KH.
Prenat Diagn 2011;31:75-83. -
Maternal serum S100 protein in normal and Down syndrome pregnancies.
Abraha HD, Noble PL, Nicolaides KH, Sherwood RA.
Prenat Diagn 1999;19:334-6. -
First trimester urine free beta hCG, beta core, and total oestriol in pregnancies affected by Down's syndrome: implications for first-trimester screening with nuchal translucency and serum free beta hCG.
Spencer K, Noble P, Snijders RJ, Nicolaides KH.
Prenat Diagn 1997;17:525-38. -
Maternal serum inhibin-A and free beta-hCG concentrations in trisomy 21 pregnancies at 10-14 weeks of gestation.
Noble PL, Wallace EM, Snijders RJ, Groome NP, Nicolaides KH.
BJOG 1997;104:367-71. -
Urinary beta-core hCG: screening for aneuploidies in early pregnancy (11-14 weeks gestation)
Macintosh MC, Nicolaides KH, Noble P, Chard T, Gunn L, Illes R.
Prenat Diagn 1997;17:401-5.